{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"103"},{"groupId":"OG001","value":"40"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"37"}]}],"title":"TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"13"}]}],"title":"TESAEs"}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"},{"groupId":"OG001","value":"42"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"40"}],"units":"Participants"}],"description":"An AE was any untoward medical occurrence in administered medicinal product, event need not necessarily have a causal relationship with product treatment or usage. A SAE was any untoward medical occurrence in a participant administered a medicinal or nutritional product (including pediatric formulas) at any dose that: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of hospitalization; resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions); resulted in congenital anomaly/birth defect. Treatment emergent AEs were events emerged during treatment period and were absent before treatment or that worsened relative to pretreatment state.","groups":[{"description":"Participants with a broader variety of hematologic malignancies and selected solid tumors, received a 0.2 mg/kg/week TTI-621 infusion until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG000","title":"Part 2: Ontorpacept (PF-07901800/TTI-621) Monotherapy"},{"description":"Participants with CTCL and PTCL, received a 0.2 mg/kg/week TTI-621 infusion. Initial 2 weeks of 0.2 mg/kg treatment followed by intraparticipant dose intensification at an increment of 0.1 mg/kg per week up to 0.5 mg/kg within 5-8 weeks until disease progression, unacceptable toxicity, or other reasons for treatment discontinuation occurred.","id":"OG001","title":"Part 3: Ontorpacept (PF-07901800/TTI-621) Monotherapy"},{"description":"Participants with cHL received 0.1 mg/kg/week TTI-621 infusion along with 3 mg/kg nivolumab given every 2 weeks or a fixed dose per current FDA approved package insert for cHL. If required dose of TTI-621 could be increased up to 0.5 mg/kg/week. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.","id":"OG002","title":"Part 2: Ontorpacept (PF-07901800/TTI-621)+ Nivolumab Combination"},{"description":"Participants with CD20-positive malignancies received 0.1 mg/kg/week TTI-621 infusion along with 375 mg/m\\^2 rituximab given weekly (1 cycle) for up to 8 cycles according to the institutional standard of care. Participants received TTI-621 monotherapy upon completion of combination partner regimen/unacceptable toxicity to the combination regimen.","id":"OG003","title":"Part 2: Ontorpacept (PF-07901800/TTI-621) + Rituximab Combination"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Analysis population included all the participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"Day 1 of dosing up to 30 days of safety follow-up visit after the last dose (maximum treatment exposure for Part 2 was 1793 days and for Part 3 was 938 days)","title":"Part 2 and 3: Number of Participants With TEAEs and TESAEs","type":"PRIMARY","unitOfMeasure":"Participants"}